NewAmsterdam Pharma (NAMS) EPS (Weighted Average and Diluted) (2023 - 2026)
NewAmsterdam Pharma's (NAMS) quarterly EPS (Weighted Average and Diluted) came in at -$0.4 in Q1 2026, down 17.65% year-on-year from -$0.49 in Q1 2025, and up 36.51% quarter-over-quarter from -$0.63 in Q4 2025.
NewAmsterdam Pharma (NAMS) EPS (Weighted Average and Diluted) (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma has disclosed EPS (Weighted Average and Diluted) across 4 years of filings, most recently posting -$0.4 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.4, down 17.65% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.79 (up 4.79% YoY), and the FY2025 annual result was -$1.72, up 32.81% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.4 for Q1 2026 at NewAmsterdam Pharma, up from -$0.63 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.15 in Q2 2025 to a low of -$1.06 in Q1 2024.
- The 4-year median for EPS (Weighted Average and Diluted) is -$0.51 (2023), against an average of -$0.53.
- Across the five-year window, EPS (Weighted Average and Diluted) jumped 68.42% in 2024 and slumped 238.89% in 2025, its largest moves.
- NewAmsterdam Pharma's EPS (Weighted Average and Diluted) stood at -$0.6 in 2023, then tumbled by 58.33% to -$0.95 in 2024, then surged by 33.68% to -$0.63 in 2025, then soared by 36.51% to -$0.4 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.4 (Q1 2026), -$0.63 (Q4 2025), and -$0.61 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | NewAmsterdam Pharma | 3.63 Bn | 3.63 Bn | - | -0.40 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.40 |
| Dec 31, 2025 | -0.63 |
| Sep 30, 2025 | -0.61 |
| Jun 30, 2025 | -0.15 |
| Mar 31, 2025 | -0.34 |
| Dec 31, 2024 | -0.95 |
| Sep 30, 2024 | -0.18 |
| Jun 30, 2024 | -0.41 |
| Mar 31, 2024 | -1.06 |
| Dec 31, 2023 | -0.60 |
| Sep 30, 2023 | -0.57 |
| Jun 30, 2023 | -0.47 |
| Mar 31, 2023 | -0.51 |